Racial and Ethnic Disparities in Menopausal Hormone Therapy Acceptance [A134]

Pershad, Anita; Morris, Joshua; Khanna, Pallavi

doi:10.1097/01.aog.0000825816.61927.41

Cited by 2 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The prior literature has also demonstrated that White women are more likely to be prescribed HRT in comparison to Black women [ 28 ]. These data are supported within the demographics of our study, listed in Table 1 .…”

Section: Discussionmentioning

confidence: 99%

The Association between Hormone Replacement Therapy and Gastroparesis in Post-Menopausal Women: A Worldwide Database Analysis

Khalil,

Hill,

Kaelber

et al. 2024

JPM

View full text Add to dashboard Cite

Female sex hormones have been hypothesized to influence the higher prevalence of gastroparesis in females. This study investigated the effects of hormone replacement therapy (HRT) on gastroparesis and its related symptoms, medication use, and diagnostic testing in post-menopausal women. Utilizing the TriNetX platform, we conducted a population-based cohort study involving post-menopausal women aged 50 or older, with and without HRT. One-to-one propensity score matching was performed to adjust for age, race, ethnicity, diabetes, body mass index (BMI), and hemoglobin A1c. The exclusion criteria included functional dyspepsia, cyclic vomiting syndrome, and surgical procedures. After applying the exclusion criteria, we identified 78,192 post-menopausal women prescribed HRT and 1,604,822 not prescribed HRT. Post-propensity matching, each cohort comprised 67,874 patients. A total of 210 of the post-menopausal women prescribed HRT developed an ICD encounter diagnosis of gastroparesis at least 30 days after being prescribed HRT compared to post-menopausal women not prescribed HRT (OR = 1.23, 95% CI [1.01–1.51] p-value = 0.0395). These associations persisted in sensitivity analysis over 5 years (OR = 1.65, 95% CI [1.13–2.41] p-value = 0.0086). HRT was associated with increased GI symptoms, including early satiety (OR = 1.22, 95% CI [1.03–1.45] p-value = 0.0187), domperidone use (OR = 2.40, 95% CI [1.14–5.02] p-value = 0.0163), and undergoing gastric emptying studies (OR = 1.67, 95% CI [1.39–2.01] p-value < 0.0001). HRT is linked to an increased risk of developing an ICD encounter diagnosis of gastroparesis.

show abstract

Section: Discussionmentioning

confidence: 99%

The Association between Hormone Replacement Therapy and Gastroparesis in Post-Menopausal Women: A Worldwide Database Analysis

Khalil,

Hill,

Kaelber

et al. 2024

JPM

View full text Add to dashboard Cite

show abstract

Systematic Reviews to Inform Practice, November/December 2024

Harris,

Howe‐Heyman

2024

J Midwife Womens Health

View full text Add to dashboard Cite

From 2016 to 2021, the rates of gestational diabetes mellitus (GDM) have increased from 6% to nearly 9%. 1 Nearly 16% of pregnancies of individuals aged 40 and older are affected by GDM. Once diagnosed with GDM, there is a 50% chance of developing type 2 diabetes mellitus (DM) within 5 years after the affected pregnancy. 2,3 Long-term health impacts of type 2 DM include cardiovascular, kidney, and retinal damage. Losing weight gained during pregnancy with a goal of returning to a baseline weight is often a challenge in the postpartum period. 4 Anxiety about being at an increased risk for a chronic condition is an additional stressor that can increase this psychosocial burden in the postpartum period.Wang et al 3 conducted a systematic review and metaanalysis to examine the efficacy of lifestyle interventions implemented in the postpartum period on the prevention of type 2 DM, glycemic outcomes, and anthropometric measures. The researchers selected 17 randomized controlled trials (RCTs) representing 5654 participants with GDM; 2825 were in experimental groups and 2829 were in control groups. Lifestyle interventions focused on various diet and physical activity types and lasted from 3 to 81 months. GDM was defined in the selected studies using criteria from World Health Organization (WHO), International Association of the Diabetes and Pregnancy Study Groups, and local diagnostic guidelines. Seven studies used the WHO criteria for gestational diabetes, and 4 articles did not describe their diagnostic criteria. The remaining 4 articles reported using other criteria that included Australasian Diabetes in Pregnancy Society, Carpenter-Coustan criteria, and the UK National Institute of Health Excellence 2015 criteria. Diagnostic methods for type 2 DM included a 75-g glucose tolerance test, fasting glucose, and the presence of oral medication or insulin use. Of the 9 studies that reported type 2 DM, 4 used the WHO criteria, one used the American Diabetes Association criteria, and 4 did not report the criteria that were used. Changes in baseline for glycemic and anthropometric measures were also assessed.Diet types included low glycemic, low calorie, and Mediterranean diets; types of physical activity included walking, resistance, moderate-intensity aerobic, and habitual physical activity. Most studies (n = 14) used both diet and exercise interventions. Intervention delivery methods included face-

show abstract

Racial and Ethnic Disparities in Menopausal Hormone Therapy Acceptance [A134]

Cited by 2 publications

References 0 publications

The Association between Hormone Replacement Therapy and Gastroparesis in Post-Menopausal Women: A Worldwide Database Analysis

The Association between Hormone Replacement Therapy and Gastroparesis in Post-Menopausal Women: A Worldwide Database Analysis

Systematic Reviews to Inform Practice, November/December 2024

Contact Info

Product

Resources

About